Gain Therapeutics announces the presentation of a poster at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, AD/PD 2024, that addresses the mechanism of action of the Company’s lead compound, GT-02287. The poster, titled “GT-02287, a Clinical Stage Glucocerebrosidase Regulator for the Treatment of PD, Eases ER Stress and Enhances Lysosomal Enzyme Activity,” which will be available online March 5th and presented on-site on the 8th and 9th by Dr. Natalia Perez-Carmona, demonstrates how GT-02287, through its interaction with glucocerebrosidase in the endoplasmic reticulum, aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme. GCase is consequently able to travel to the lysosome, resulting in enhanced lysosomal activity and efficient processing of the GCase substrate glucosylceramide. Increase in GCase substrate in the lysosome was previously shown to be associated with accumulation of aggregated alpha-synuclein, a pathological hallmark of Parkinson’s disease and related disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GANX:
- Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
- Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
- Gain Therapeutics to host research and development day
- Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
- UPDATE – Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease